KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm. 2026;40(1):5-12 / www.klinickafarmakologie.cz 12 PŮVODNÍ PRÁCE Významné postavenie gliflozínov v terapii diabetes mellitus 2. typu 24. Wilding, JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014;63:1228-1237. 25. Yakovleva T, Sokolov V, Chu L, et al. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: a quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes Obes Metab. 2019; 21:2684-2693. 26. NCZI, štatistické výstupy 2023. [Internet]. Available from: https://www.nczisk.sk/Statisticke_vystupy/Tematicke_statisticke_vystupy/Diabetologia/Pages/default.aspx. 27. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. 28. Galwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. 29. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin addon to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-789. 30. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562-576. 31. Tkac I, Raz I. Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. Diabetes Care. 2017;40(2):284-286. 32. Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098-2107. 33. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255-270. 34. Galajda P, Samoš M, Bolek T, et al. Desať rokov liečby pacientov s diabetes melitus 2. typu gliflozínmi. Forum Diabetologicum. 2023;12(2):76-83. 35. Bosch A, Ott C, Jung S, et al. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):44. 36. Covie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761-772. 37. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A State-of-the- Art Review. JACC Basic Transl Sci. 2020;5(6):632-644. 38. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A „Thrifty Substrate“ Hypothesis. Diabetes Care. 2016;39(7):1108-1114. 39. Sarwar N, Gao P, Kondapally Seshasai SR, et al. Emerging Risk Factors Collaboration; Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-2222. 40. Lingvay I, Sumithran P, Cohen RV, et al. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399:394-405. 41. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44:2438-2444. 42. Uličianský V, Schroner Z. Inhibítory sodíkovo-glukózového kotransportéra 2 (SGLT2) vs. Inhibítory dipeptidyl-peptidázy 4 (DPP4). Súčasná klinická prax. 2016;13(2):16-25. 43. Prázný M, Slíva J. Empagliflozin – nový zástupca inhibitoru transportétu SGLT2 pro léčbu pacientu s diabetem 2. typu. Vnitř lék. 2015;61(2):175-178. 44. Schroner Z. Inhibítor SGLT2 kanagliflozín: benefity v liečbe diabetes mellitus 2. typu. Diabetes a obezita 2023;23(45): 63-64. 45. Sánchez-García A, Simental-Mendía M, Millán-Alanís JM, et al. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020;160:105068. 46. Kern M, Klöting N, Mark M, et al. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016;65(2):114-123. 47. Filippas-Ntekouan S, Tsimihodimos V, Filippatos T, et al. SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert Opinion on Drug Metabolism & Toxicology. 2018;14(11):1113-1121. 48. Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism. Diabetes. 2016;65(7):2032-2038. Datum: 9.–11. 9. 2026 Místo: Univerzitní kampus Bohunice, Kamenice 753/5, Brno Společná konference farmakologických a toxikologických společností: 73. Česko-slovenské farmakologické dny 31. konference TOXCON 29. Česká konference TDM 25. Česká konference klinické farmakologie Společná konference farmakologických a toxikologických společností SAVE THE DATE Česká společnost pro experimentální a klinickou farmakologii a toxikologii
RkJQdWJsaXNoZXIy NDA4Mjc=